SCHEMBL4784791

SCHEMBL4784791

CC(C)Oc1ccc(-n2c(C3CCCCC3)nc(O)cc2=O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 3/20 0.42
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.39
HPGD P15428 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
DRD1 P21728 2/20 0.39
DRD5 P21918 2/20 0.39
ADCY1 Q08828 1/20 0.39
PDE9A O76083 2/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
USP2 O75604 2/20 0.38
KDM4E B2RXH2 2/20 0.38
HTT P42858 1/20 0.38
LMNA P02545 1/20 0.38
MAT2A P31153 1/20 0.36
MITF O75030 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4741828 0.89 APLNR (0.44) APLNRALDH1A1DRD1DRD5MEN1
SCHEMBL4784797 0.82 APLNR (0.48) APLNRALDH1A1MAPTPOLBHPGD
SCHEMBL4741076 0.81 KMT2A (0.42) APLNRALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL4739124 0.81 HPGD (0.43) APLNRALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL4737525 0.80 KMT2A (0.54) APLNRALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL4742638 0.80 ALDH1A1 (0.40) APLNRALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL17317042 0.76 APLNR (0.51) APLNRALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL4739975 0.75 KMT2A (0.38) APLNRALDH1A1DRD1DRD5MEN1
SCHEMBL4782896 0.75 KMT2A (0.44) APLNRALDH1A1SMN1; SMN2DRD1DRD5
SCHEMBL4739974 0.74 ALDH1A1 (0.38) APLNRALDH1A1MAPTPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 APLNR 2034/4885ALDH1A1 513/4885MAPT 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.